Clinical trials: Carcinoma, Bronchogenic
Non Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
This is a phase II, prospective, multi-centre study. To assess the efficacy and safety of furmonertinib in patients with epidermal growth factor receptor 20ins mutation positive stage IB-IIIA Non-small Cell Lung Carcinoma…
- Trial name
- NCT06192849
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Juan LI, MD
Lung Cancer
Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00084799
- Testing
- monoclonal antibody hu3S193
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ludwig Institute for Cancer Research
Lung Cancer, Metastatic Cancer
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
RATIONALE: Treatment with radiosurgery, temozolomide, and erlotinib may affect brain function (the ability to think, learn, remember, and judge) in patients with non-small cell lung cancer and brain metastases.
- Trial name
- NCT00385398
- Testing
- erlotinib hydrochloride, temozolomide, stereotactic radiosurgery
- Sponsor
- University of Medicine and Dentistry of New Jersey
Lung Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung (NSCLC)
Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma
The goal of this clinical trial is to learn if adding intermittent hypoxic training (IHT) to standard neoadjuvant chemo-immunotherapy can increase the pathologic complete response (pCR) rate in patients aged 18 to 75 of both…
- Trial name
- NCT07618793
- Testing
- Intermittent Hypoxic Training (IHT), Standard Neoadjuvant Chemo-immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- zhang yi
Carcinoma, Giant Cell, Carcinoma, Non-Small-Cell Lung
Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma
This study will help us understand the gene expression profiles of lung cancer. We will identify genes related to lung cancer development, their growth and metastasis to the lung.
- Conditions
- Carcinoma, Giant Cell, Carcinoma, Non-Small-Cell Lung, Lung Cancer
- Trial name
- NCT00568906
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Stanford University
Ovarian Cancer, Renal Cancer
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
The primary objectives of this Phase 1b/2 study were as follows: Phase 1b (Bolus and Infusion): To evaluate the safety and tolerability of carfilzomib in patients with relapsed solid tumors and in patients with relapsed and/or…
- Conditions
- Ovarian Cancer, Renal Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT00531284
- Testing
- Carfilzomib, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 184 people
- Sponsor
- Amgen
Carcinoma, Non-Small-Cell Lung
Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
This is an open-label, multicenter, multiple-dose, Phase I-II study of CHR-2797 co-administered with erlotinib in patients with histologically or pathologically confirmed Stage IIIB (with pleural effusion), Stage IV, or recurrent…
- Trial name
- NCT00522938
- Testing
- CHR-2797 (tosedostat), erlotinib
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Chroma Therapeutics
Relapsed/Refractory Small Cell Lung Cancer
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
The main aim of this study is to: evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of tarlatamab for Part 1 only evaluate anti-tumor…
- Trial name
- DeLLphi-301 (NCT05060016)
- Testing
- Tarlatamab
- Where
- 80 sites in United States, Austria and 16 more
- Volunteers
- 222 people
- Sponsor
- Amgen
Carcinoma, Non-Small-Cell Lung
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
This study determines tumor response rate, time to tumor progression and survival rate at 1 year produced by OSI-774 in previously treated African American patients with nonsmall cell lung cancer.
- Trial name
- NCT00230126
- Testing
- erlotinib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Small Cell Lung Cancer, Brain Metastases, Adult
Tarlatamab for SCLC Brain Metastases
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
- Trial name
- T-BRAIN (NCT07402343)
- Testing
- Tarlatamab
- Where
- 4 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- Maastricht University Medical Center
Non-Small Cell Lung Cancer (NSCLC)
An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin
This is an open-label dose escalation trial using ABI-007 plus carboplatin.
- Trial name
- NCT00274443
- Testing
- ABI-007 (Abraxane) and Carboplatin
- Where
- Russia
- Volunteers
- 250 people
- Sponsor
- Celgene
Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
The third generation epidermal growth gactor receptor-tyrosine Kinase Inhibitor（EGFR-TKI） osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID 27959700), but acquired drug resistance will…
- Conditions
- Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, EGFR T790M
- Trial name
- NCT03532698
- Testing
- Aspirin, Osimertinib
- Volunteers
- 100 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non Small Cell Lung Cancer
A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit angiogenesis-related kinases, such as VEGFR, FGFR, PDGFR and tumor cell proliferation related kinase c-Kit…
- Trial name
- NCT04619563
- Testing
- Anlotinib Hydrochloride plus Docetaxel
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shandong Cancer Hospital and Institute
Small Cell Lung Cancer
Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer
The majority of small cell lung cancer(SCLC)(50-100%) express somatostatin receptors(type 1-5) with some small cell lung cancer express more than one subtypes.
- Trial name
- NCT01417806
- Testing
- Topotecan and Pasireotide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- South Florida Veterans Affairs Foundation for Research and Education
Head and Neck Cancer, Lung Cancer
Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00021333
- Testing
- filgrastim, cisplatin, paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
Non-small Cell Lung Cancer
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
The purpose of this study is to examine the overall survival of patients with Stage IV non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin and paclitaxel.
- Trial name
- NSCLC (NCT01234038)
- Testing
- ISIS EIF4E Rx, Paclitaxel, Carboplatin
- Where
- 29 sites in United States, Hungary and 2 more
- Volunteers
- 116 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Non Small Cell Lung Cancer
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
The purpose of this study is to improve disease control and survival for patients who were treated with chemotherapy using BMS-690514 over erlotinib
- Trial name
- NCT00743938
- Testing
- BMS-690514, Erlotinib
- Where
- 30 sites in United States, Argentina and 6 more
- Volunteers
- 141 people
- Sponsor
- Bristol-Myers Squibb
Lung Neoplasm, Carcinoma, Bronchogenic
Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer
In this Phase II clinical trial the investigators will use four human non-small cell lung cancer cell lines that have been previously established in tissue culture laboratory.
- Trial name
- NCT01058785
- Testing
- Lucanix
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- NovaRx Corporation
Carcinoma, Non-Small-Cell Lung
Feasibility of an Acute Physical Exercise Before Treatment Infusion for Metastatic Lung Cancer Patients
Because of metastatic Non-Small Cell Lung Cancer (mNSCLC) and its treatments, patients suffer from numerous symptoms such as dyspnea, muscle atrophy, pain, fatigue, loss of appetite, altered physical condition and lung function…
- Trial name
- ERICA (NCT04676009)
- Testing
- Exercise arm :
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Centre Leon Berard
Lung Cancer
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00660816
- Testing
- erlotinib hydrochloride, pemetrexed disodium, docetaxel
- Where
- 13 sites in United States
- Volunteers
- 46 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.